Type I Interferons Impede Short Hairpin RNA-Mediated RNAi via Inhibition of Dicer-Mediated Processing to Small Interfering RNA

Mitsuhiko Machitani,1,2 Fuminori Sakurai,1,3 Keisaku Wakabayashi,1 Kosuke Takayama,1 Masashi Tachibana,1 and Hiroyuki Mizuguchi1,4,5,6,7

1Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan; 2Institute for Frontier Life and Medical Sciences, Kyoto University, 53 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan; 3Laboratory of Regulatory Sciences for Oligonucleotide Therapeutics, Clinical Drug Development Unit, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan; 4Laboratory of Hepatocyte Regulation, National Institutes of Biomedical Innovation, Health and Nutrition, 7-6-8 Saito, Asagi, Ibaraki, Osaka 567-0085, Japan; 5IPS Cell-Based Research Project on Hepatic Toxicity and Metabolism, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan; 6Global Center for Advanced Medical Engineering and Informatics, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan; 7Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan

RNAi by short hairpin RNA (shRNA) is a powerful tool not only for studying gene functions in various organisms, including mammals, but also for the treatment of severe disorders. However, shRNA-expressing vectors can induce type I interferon (IFN) expression by activation of innate immune responses, leading to off-target effects and unexpected side effects. Several strategies have been developed to prevent type I IFN induction. On the other hand, it has remained unclear whether type I IFNs have effects on shRNA-mediated RNAi. Here, we show that the type I IFNs significantly inhibit shRNA-mediated RNAi. Treatment with recombinant human IFN-α significantly inhibited shRNA-mediated knockdown of target genes, while it did not inhibit small interfering RNA (siRNA)-mediated knockdown. Following treatment with IFN-α, increased and decreased copy numbers of shRNA and its processed form, respectively, were found in the cells transfected with shRNA-expressing plasmids. Dicer protein levels were not altered by IFN-α. These results indicate that type I IFNs inhibit shRNA-mediated RNAi via inhibition of dicer-mediated processing of shRNA to siRNA. Our findings should provide important clues for efficient RNAi-mediated knockdown of target genes in both basic researches and clinical gene therapy.

INTRODUCTION

Chimically synthesized small interfering RNAs (siRNAs) or vectors expressing short hairpin RNA (shRNA) are widely used to induce RNAi in vitro and in vivo not only for gene-function analysis in basic research but also for the treatment of severe disorders due to their superior knockdown efficiencies.1-3 siRNAs are transfected into cells using transfection reagents in the form of ~21- to 23-bp double-stranded RNA (dsRNA), whereas shRNAs are delivered by non-viral or viral vectors encoding shRNA. Following the introduction of shRNA-expressing vectors into cells, shRNAs are transcribed mainly via the polymerase (pol) III promoter, exported from the nucleus to the cytoplasm by exportin 5, and processed by the endoribonuclease dicer to siRNAs. The generated siRNAs are then incorporated into the RNA-induced silencing complex (RISC) and guide the RISC to the target mRNA in an siRNA-sequence-specific manner, leading to knockdown of the target gene.1-3 Among the RISC components, argonaute 2 (Ago2) cleaves target mRNA, while Ago1, Ago3, and Ago4 do not possess cleavage activities.4

Following introduction of non-viral and viral vectors into cells, innate immune responses, including type I interferon (IFN) responses, are triggered.5,6 The induction of type I IFN responses results in upregulation of a large number of IFN-stimulated genes (ISGs), suggesting that expression levels of various non-target genes as well as target genes are altered by type I IFNs. The type I IFN responses might affect shRNA-mediated RNAi by positively or negatively regulating the RNAi pathway.

In this study, we demonstrate that the type I IFNs significantly inhibit shRNA-mediated RNAi via inhibition of dicer-mediated processing of shRNA to siRNA. Since siRNA-mediated knockdown was not impeded by type I IFNs. These data suggest that care should be taken when using shRNA-expressing vectors in either basic research or clinical gene therapy, since they can induce type I IFN
production that may in turn inhibit the knockdown efficiencies of shRNAs.

RESULTS

Type I IFN Responses following Introduction of shRNA-Expressing Vectors

In order to examine whether type I IFN expression was induced following introduction of shRNA-expressing plasmids and siRNAs, A549 and H1299 cells were transfected with a plasmid expressing shRNA against luciferase (shLuc) (pHMU6-shLuc) or a control siRNA (siControl). Treatment of both cells with recombinant type I IFN (IFN-α) significantly induced ISG expression (Figure S1). qRT-PCR analysis showed that transfection with the shLuc-expressing plasmid significantly induced high levels of IFN-β and ISG expression (Figures 1A and 1B), whereas significant levels of upregulation of IFN-β and ISG expression were not found following transfection with the siControl (Figures 1C and 1D). Next, we examined whether an shRNA-expressing plasmid would induce type I IFN responses in vivo. Intramuscular administration of the shLuc-expressing plasmid induced high levels of IFNβ expression (more than 100-fold compared to the PBS-administered group) (Figure 1E). These results indicate that introduction of shRNA-expressing plasmids, but not siRNAs, induces type I IFN responses, leading to elevation in ISG expression levels.

IFN-α Stimulation Inhibited shRNA-Mediated Gene Knockdown

In order to examine whether type I IFNs affect shRNA-mediated knockdown efficiencies, H1299 and A549 cells were transfected with shRNA-expressing plasmids, followed by treatment with recombinant human IFN-α. The cell viabilities (Figure S2) and transfection efficiencies, which were assessed by the percentages of GFP-positive cells following transfection with a GFP-expressing plasmid (Figure S3), were not significantly altered after 43-hr exposure to 10⁴ U/mL IFN-α. In H1299 cells, transfection with an shRNA against c-myc (shmyc)-expressing plasmid (pHMU6-shmyc) led to significant knockdown of the c-myc gene in the absence of IFN-α stimulation (Figures 2A and 2B). Surprisingly, c-myc-knockdown efficiencies were reduced by ~35% when cells were treated with IFN-α (Figure 2A). In agreement with the shRNA-mediated alteration of c-myc mRNA levels, knockdown of c-myc at the protein level was also inhibited by IFN-α stimulation (Figure 2B). mRNA and protein levels of c-myc were not significantly altered after treatment with 10⁴ U/mL IFN-α (Figures 2A and 2B). The reduction in the knockdown efficiencies of pHMU6-shmyc by IFN-α was dependent on the doses of IFN-α (Figure 2C). IFN-α inhibited target gene knockdown in A549 cells when mediated not only by shmyc but also by shRNA against p53 (shp53) (Figures 2D and 2E). Treatment with recombinant human IFN-β, which is another type I IFN, also inhibited shmyc-mediated knockdown in H1299 cells (Figure 3A). On the
other hand, a type II IFN (IFN-\(\gamma\)) did not alter the knockdown efficiencies of an shmyc-expressing plasmid, although a slight but statistically significant inhibition of shmyc-mediated knockdown was found following treatment with tumor necrosis factor \(\alpha\) (TNF-\(\alpha\)), which is a representative inflammatory cytokine (Figure 3B). Next, in order to examine whether the results described above were found only when the U6 promoter was used as an shRNA-expressing promoter, we tested a plasmid containing an H1-promoter-driven shmyc-expression cassette (pHMHI-shmyc). Treatment with IFN-\(\alpha\) significantly inhibited shmyc-mediated knockdown of the c-myc gene following transfection with pHMH1-shmyc (Figures 4A and 4B), suggesting that type I IFNs inhibit knockdown by an shRNA driven by any type of pol III promoter. These results suggest that type I IFNs inhibit shRNA-mediated knockdown, at least within 43 hr after type I IFN treatment.

Knockdown by Chemically Synthesized siRNAs Was Not Inhibited by IFN-\(\alpha\) Stimulation

Following transfection with shRNA-expressing plasmids, an shRNA is transcribed and processed to siRNA by dicer, leading to the knockdown of target genes. We next examined the effects of type I IFNs on chemically synthesized siRNA-mediated knockdown. When A549 cells were transfected with an siRNA against p53 (sip53), followed by incubation in the presence of recombinant human IFN-\(\alpha\), p53 was significantly knocked down at comparable levels in the presence or absence of IFN-\(\alpha\) (Figure 5A). Similar results were found in an siRNA against c-myc (simyc)-transfected cells (Figure 5B). These results suggest that type I IFNs do not inhibit siRNA-mediated knockdown and that steps before the incorporation of siRNA into RISC are impaired by type I IFNs.

IFN-\(\alpha\) Stimulation Inhibited Dicer-Mediated Processing of shRNA to siRNA

Next, in order to examine the copy numbers of shRNA and the processing product, siRNA, northern blotting analysis was performed following transfection with shRNA-expressing plasmids. Copy numbers of shp53 and shmyc were increased by IFN-\(\alpha\) stimulation in H1299 cells transfected with shp53- and shmyc-expressing
mobility shift of Ago2 were observed in the presence and absence of IFN-α by western blotting analysis using Phos-tag gels, indicating that the phosphorylation levels of Ago2 were comparable between the IFN-α-treated group and vehicle-treated group (Figure S6B). These results suggest that the expression levels of dicer, Ago2, and TRBP, which are representative components of the RNAi pathway, are not significantly affected by IFN-α stimulation.

**PKR Had No Effect on Type I IFN-Mediated Inhibition of the Processing of an shRNA**

dsRNA-dependent protein kinase (PKR) is rapidly upregulated by type I IFNs at the mRNA and protein levels (Figures S1A and S7A). TRBP, which supports dicer function, binds to PKR and functions as an inhibitor of PKR, raising the possibility that PKR might capture TRBP and competitively impair its ability to process an shRNA following type-I-IFN-mediated upregulation of PKR. We evaluated the processing efficiencies of an shRNA to an siRNA in PKR-knockdown cells in order to examine the involvement of PKR in type I IFN-mediated inhibition of the processing of an shRNA. Comparable levels of sip53 were produced from shp53 in PKR-knockdown cells with or without IFN-α treatment (Figure S7B), indicating that siRNA-mediated PKR knockdown did not cancel the IFN-α-mediated inhibition of the processing of an shRNA. These results suggest that PKR has no effect on type I IFN-mediated inhibition of the processing of an shRNA.

**IFN-α Stimulation Also Inhibited the Knockdown Efficiencies of an shRNA-Expressing Adenovirus Vector**

The adenovirus (Ad) vector is a powerful framework for shRNA-mediated knockdown due to its superior transduction efficiencies. We examined whether an shRNA-expressing Ad vector would induce type I IFN responses. Intravenous administration of an Ad vector expressing shLuc (Ad-shLuc) induced ~500-fold higher levels of expression of IFN-α in the spleen compared with administration of PBS (Figure 8A). In order to examine whether type I IFNs inhibit the knockdown efficiencies of Ad vectors expressing shRNA, A549 cells were transduced with an Ad vector expressing shp53 (Ad-shp53), followed by treatment with recombinant human IFN-α. The transduction efficiencies of the Ad vector were not
altered by treatment with IFN-α (Figure S8). The copy numbers of the siRNA produced by processing from shp53 were significantly reduced following IFN-α stimulation in the cells following transduction with Ad-shp53 (Figure 8B). An ~15% decrease in the knockdown efficiencies of Ad-shp53 was observed following treatment with IFN-α (Figure 8C). Ad-shp53-mediated knockdown of p53 protein was also inhibited by IFN-α stimulation (Figure 8D). These results suggest that type I IFNs also inhibit Ad-vector-expressing shRNA-mediated knockdown via inhibition of the processing of shRNA to siRNA.

**DISCUSSION**

The aim of this study was to investigate the effects of type I IFNs on shRNA-mediated RNAi and to provide insights that could lead to more efficient knockdown by shRNA. The results showed that type I IFNs inhibit the processing of shRNA to siRNA (Figure 4), leading to a reduction in the knockdown efficiencies of shRNA-expressing plasmids (Figures 1 and 2) and shRNA-expressing Ad vectors (Figure 6). On the other hand, synthetic siRNA-mediated knockdown of target genes was not altered by IFN-α stimulation (Figure 3).

This study demonstrated that IFN-α treatment leads to apparent inhibition of the processing of shRNA to siRNA (Figure 4). Several previous studies also suggested that the RNAi pathway was negatively regulated by innate immune responses. Wiesen et al. reported that treatment with type I IFN or transfection with poly(L:C), a synthetic analog of double-stranded RNA that strongly induces type I IFN production, suppressed dicer protein levels in the trophoblast cells; however, they did not examine whether the dicer expression levels were suppressed by type I IFNs in other types of mammalian cells. We demonstrated that mRNA and protein levels of dicer were not significantly reduced by IFN-α stimulation in H1299 and A549 cells (Figures 5A and 5B). Type-I-IFN-mediated suppression of dicer expression might occur only in limited types of cells. Seo et al. demonstrated that infection with Sendai virus and herpes simplex virus leads to a reduction in mammalian RNAi activity via modification of Ago2 by poly-ADP-ribose and that this effect is mediated by RIG-I/ mitochondrial anti-viral signaling adaptor (MAVS)-dependent signaling. The RIG-I-MAVS pathway is involved in type I IFN production following virus infection; however, we demonstrated that IFN-α stimulation did not significantly induce the ribosylation of Ago2 by poly-ADP-ribose (Figure 5C). This suggests that the modification of Ago2 by poly-ADP-ribose is triggered not by the type I IFN production pathway but by other downstream pathways via RIG-I-MAVS signaling.

Several studies have demonstrated that type I IFN responses are induced following introduction of siRNA and shRNA. However, transfection with an siRNA did not also induce detectable levels of IFN responses in the cultured cells in this study (Figures 1C and 1D). Previous studies also demonstrated that introduction of siRNA alone did not induce type I IFN expression. siRNA-induced type I IFN responses would be caused under restricted situations. On the other hand, introduction of an shRNA-expressing plasmid significantly induced type I IFN responses (Figures 1A, 1B, and 1E). The type I IFN responses induced by the shRNA-expressing vector might affect the knockdown efficiencies of shRNAs.

As shown in Figure 5A, processing of pre-miRNAs was hardly affected by IFN-α treatment. This might have been due to the high processing efficiency of pre-miRNAs to mature miRNAs. As shown in Figure S5A, pre-let-7a, -miR-27a, and -miR-17 were not significantly induced by Northern blotting analysis, whereas detectable levels of mature let-7a, miR-27a, and miR-17 were found. These results suggest that IFN-α did not sufficiently inhibit pre-miRNA processing under this condition and that the IFN-α-mediated inhibition of the processing of shRNA was different from that of pre-miRNA.

Viral and non-viral vectors expressing an shRNA are a promising agent for severe disorders. Various pre-clinical studies using shRNA-expressing vectors have been reported. For example, several studies demonstrated that shRNAs against mRNAs of hepatitis B virus (HBV) and hepatitis C virus (HCV) efficiently inhibited the virus replication in culture cells and in mice. On the other hand, treatment with pegylated IFN-α (PEG-IFN) is often chosen for therapy against persistent infection with HBV and HCV. The combination of therapies with PEG-IFN and shRNA against HBV and HCV should be performed with caution, because PEG-IFN inhibits the therapeutic efficacy of shRNA against HBV and HCV. Viral and non-viral vectors expressing an shRNA have also been widely tested as potential anti-cancer agents. The drug packaging insert for PEG-IFN

![Figure 4. IFNs-Mediated Inhibition of Knockdown following H1 Promoter-Driven Expression of shRNA](image-url)
In this study, IFN-α-mediated inhibition of the knockdown efficiencies of shmyc was statistically significant, but not larger than expected based on the level of IFN-α-mediated reduction in simyc copy numbers (Figure 2A). More than 50% reduction in simyc copy numbers was observed after IFN-α treatment (Figure 6B). Even if the simyc copy numbers were in fact reduced to this degree, sufficient levels of simyc for knockdown of c-myc were produced in IFN-α-stimulated cells. In addition, the effects of type I IFNs on shRNA-mediated RNAi differ between cell types, target genes, and delivery vectors.

In summary, we have demonstrated that type I IFNs inhibit shRNA-mediated RNAi via inhibition of the processing of shRNA to siRNA. This study suggests that it is important to avoid IFN responses for the efficient knockdown of target genes not only in basic research but also in medical studies.

MATERIALS AND METHODS

Cells and Mice

HEK293 (a transformed embryonic kidney cell line) and A549 (a human lung adenocarcinoma epithelial cell line) cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS), streptomycin (100 μg/mL), and penicillin (100 U/mL). H1299 (a non-small cell lung carcinoma cell line) cells were cultured in RPMI 1640 supplemented with 10% FBS, streptomycin (100 μg/mL), and penicillin (100 U/mL). Female C57BL/6 mice aged 6 weeks were obtained from Nippon SLC. The mouse experimental procedures used in this study were approved by the Animal Experimentation Committee of Osaka University and performed in accordance with the institutional guidelines for animal experiments at Osaka University.

Reagents

Recombinant human IFN-α, IFN-β, and IFN-γ were purchased from PBL Interferon Source. Recombinant human TNF-α was purchased from Invivogen.

Plasmids

The plasmids expressing shRNA against luciferase (shLuc), p53 (shp53), and c-myc (shmyc) were previously constructed.2,3 Briefly, in order to insert the sequences that encode shLuc, shp53, and shmyc, the corresponding oligonucleotides were synthesized, annealed, and cloned under the human U6 and H1 promoter sequences in the two types of plasmids, pHMS-U6 and -H1,2,3 resulting in pHM-U6-shLuc, -U6-shp53, -U6-shmyc, pHM-H1-shLuc, -H1-shp53, and -H1-shmyc. pHMCMV-GFP, a plasmid expressing GFP, was also previously constructed.34
Viruses

The Ad vectors expressing shLuc and shp53 under the human U6 promoter (Ad-shLuc and -shp53, respectively) were previously prepared by in vitro improved ligation method.14,35,36 The Ad vector expressing GFP (Ad-GFP) was also previously prepared.34 These Ad vectors were amplified in HEK293 cells and purified by two rounds of cesium-chloride-gradient ultracentrifugation, dialyzed, and stored at −80°C.35 The virus particles (VPs) were determined by a spectrophotometric method.35 Determination of infectious units (IFU) was accomplished using an Adeno-X Rapid Titer Kit (Clontech Laboratories).

Transfection with siRNAs and shRNA-Expressing Plasmids

Control siRNA (siControl) was purchased from QIAGEN (Allstars Negative Control siRNA, QIAGEN). sip53, simyc, and siRNA against PKR (siPKR) were obtained from Gene Design. The target sequences of sip53, simyc, and siPKR were 5'-ctaccttgaaacaacg-3', 5'-gatgaggaagaatcgatg-3', and 5'-gtgtaagtagataaaga-3', respectively. Efficient knockdown of PKR after transfection with siPKR was previously demonstrated.37

Cells were transfected with siRNAs at 50 nM or shRNA-expressing plasmids or were transduced with Ad vectors at the indicated titers. After 5-hr incubation, the cells were treated with recombinant cytokines, including IFN-α, and incubated for a total of 48 hr. Expression levels of target genes were evaluated as described below.

qRT-PCR Analysis

Cells were transfected with siRNAs or shRNA-expressing plasmids or were transduced with Ad vectors at the indicated titers. After 5-hr incubation, the cells were treated with recombinant IFN-α and incubated for a total of 48 hr. Total RNA was isolated from the cells using ISOGEN (Nippon Gene). cDNA was synthesized using 500 ng total RNA with a Superscript VILO cDNA synthesis kit (Life Technologies). Real-time RT-PCR analysis was performed using Fast SYBR Green Master Mix (Life Technologies) and a StepOnePlus real-time
PCR system (Life Technologies) as previously described. The data were normalized by glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA levels. Sequences of the primers used in this study are described in Table S1.

siRNA copy numbers were determined by qRT-PCR using Mir-X miRNA First-Strand Synthesis and SYBR qRT-PCR (Clontech-Takara) and primers specific for the sip53 and simyc. Sequences of the primers used in this study are described in Table S1.

**Determination of Type I IFN Expression Levels In Vivo**

100 µg shLuc-expressing plasmid (pHMU6-shLuc) and 4 × 10⁸ IFU Ad-shLuc were intramuscularly and intravenously administered to mice, respectively. Total RNA was extracted from the muscles and spleens 3 hr after intramuscular and intravenous administration, respectively. Type I IFN mRNA levels were determined by qRT-PCR analysis.

**Western Blotting Analysis**

Western blotting analysis was performed as previously described. Briefly, whole-cell extracts were prepared and electrophoresed on 10% SDS-polyacrylamide gels under reducing conditions, followed by electrotransfer to polyvinylidene fluoride (PVDF) membranes (Millipore). After blocking with 5% skim milk prepared in TBS-T (Tween-20; 0.1%), the membrane was incubated with primary antibodies (Table S2), followed by incubation in the presence of horseradish peroxidase (HRP)-labeled anti-rabbit or anti-mouse immunoglobulin G (IgG) antibody (Cell Signaling Technology). Phosphorylation levels of Ago2 were determined by western blotting analysis using Phos-tag polyacrylamide gels (Wako), as previously described.

**Northern Blotting Analysis**

Total RNA was extracted from the cells with ISOGEN (Nippon Gene). 10 µg total RNA per lane was loaded onto 15% polyacrylamide denaturing gel. After electrophoresis, bands of RNA were transferred to Hybond-N+ membranes (Roche). The membranes were then probed with ³²P-labeled synthetic oligonucleotides that were complementary to the sequence of sip53, simyc, let-7a, or human U6 small nuclear RNA (sip53: 5'-gactccagtggtaatctac-3'; simyc: 5'gatgaggaagaaatcgatg-3'; let-7a: aactatacaacctactacctca; U6: 5'tgctaatcttctgatgtc-3').

**Determination of Poly-ADP-Ribosylation Levels of Ago2**

Whole-cell extracts were prepared from IFN-α-stimulated cells, and Ago2 was immunoprecipitated using a mouse anti-Ago2 antibody (Table S2) and a microRNA Isolation Kit (human Ago2) (Wako). After immunoprecipitation, poly-ADP-ribosylation levels of the immunoprecipitated Ago2 were determined by western blotting analysis using a mouse anti-pADPr antibody (Table S2).

**Statistical Analysis**

Statistical significance was determined using the Student’s t test. Data are presented as the means ± SD or SE.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes eight figures and two tables and can be found with this article online at http://dx.doi.org/10.1016/j.omtn.2016.12.007.

**AUTHOR CONTRIBUTIONS**

M.M. designed and performed the experiments, analyzed data, and wrote the manuscript; F.S. designed and supervised the projects, analyzed data, and wrote the manuscript; K.W. and K.T. supported...
the experiments: M.T. analyzed data; and H.M. supervised the projects, interpreted data, and wrote the manuscript.

CONFLICTS OF INTEREST
The authors declare no competing financial interests.

ACKNOWLEDGMENTS
We thank Sayuri Okamoto and Eri Hosoyamada (Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan) for their help. This work was supported by grants-in-aid for Scientific Research (A, 26242048; B, 26293118) from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan, grants from the Japan Research Foundation for Clinical Pharmacology, the Mochida Memorial Foundation for Medical and Pharmaceutical Research, and the Daiwa Securities Health Foundation, a grant-in-aid from the Ministry of Health, Labour, and Welfare (MHLW) of Japan, and a grant from the Japan Agency for Medical Research and Development (AMED) (15km0310017h0004). M.M. and K.W. are Research Fellows of the Japan Society for the Promotion of Science.

REFERENCES
1. Scherer, I.L., and Rossi, J.J. (2003). Approaches for the sequence-specific knockdown of mRNA. Nat. Biotechnol. 21, 1457–1465.
2. Tuscher, T. (2002). Expanding small RNA interference. Nat. Biotechnol. 20, 446–448.
3. Witttrap, A., and Lieberman, J. (2015). Knocking down disease: a progress report on siRNA therapeutics. Nat. Rev. Genet. 16, 543–552.
4. Huttunen, G., and Simard, M.J. (2008). Argonaute proteins: key players in RNA silencing. Nat. Rev. Mol. Cell Biol. 9, 22–32.
5. Sakurai, H., Kawabata, K., Sakurai, F., Nakagawa, S., and Mizuguchi, H. (2008). Innate immune response induced by gene delivery vectors. Int. J. Pharm. 354, 9–15.
6. Bessis, N., Garcia-Cazor, F.J., and Boissier, M.C. (2004). Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. 11 (Suppl 1), S10–S17.
7. Winter, J., Jung, S., Keller, S., Gregory, R.I., and Diederichs, S. (2009). Many roads to siRNA therapeutics. Nat. Rev. Genet. 10, 354–365.
8. Leung, A.K., Vyas, S., Rood, J.E., Bhutkar, A., Sharp, P.A., and Chang, P. (2011). siRNA therapeutics. Nat. Rev. Genet. 12, 7–17.
9. Hutvagner, G., and Simard, M.J. (2008). Argonaute proteins: key players in RNA silencing. Nat. Rev. Genet. 16, 543–552.
10. Hatta, K., Kato, H., Sato, S., Yonehara, M., Yamamoto, M., Uematsu, S., Matsu, K., Tsujimura, T., Takeda, K., Fujita, T., Takachiki, O., and Akira, S. (2005). Cell type-specific involvement of RIG-I in antiviral response. Immunity 23, 19–28.
11. Sleda, C.A., Holko, M., de Veer, M.J., Silverman, R.H., and Williams, B.R. (2003). Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5, 834–839.
12. Bridge, A.J., Pfeffer, S., Druce, A., Nicoulaud, A.L., and Igo, R. (2003). Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet. 34, 263–264.
13. Beger, M., Bonnin, P., Sulpice, E., Vilar, J., Allanic, D., Silvestre, J.S., Lévê, B.J., Tucker, G.C., Tobelem, G., and Merkulova-Raisin, T. (2010). Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma. Am. J. Pathol. 177, 3192–3201.
14. Chen, X., Qian, Y., Yan, F., Tu, J., Yang, X., Xing, Y., and Chen, Z. (2013). 5′-triphosphate-siRNA activates RIG-I-dependent type I interferon production and enhances inhibition of hepatitis B virus replication in HepG2.2.15 cells. Eur. J. Pharmacol. 721, 86–95.
15. McCaffrey, A.P., Nakai, K., Pandey, K., Huang, Z., Salazar, F.H., Xu, H., Wieland, S.F., Marion, P.L., and Kay, M.A. (2003). Inhibition of hepatitis B virus in mice by RNA interference. Nat. Biotechnol. 21, 659–664.
16. Carmona, S., Ely, A., Crowther, C., Moodi, N., Salazar, F.H., Marion, P.L., Ferry, N., Weinberg, M.S., and Arbuthnot, P. (2006). Effective inhibition of HBV replication in vivo by anti-HBs short hairpin RNAs. Mol. Ther. 13, 411–421.
17. Vlassov, A.V., Korb, B., Farrar, K., Mukerjejer, S., Seyhan, A.A., Ilves, H., Kaspar, R.L., Leake, D., Kazakov, S.A., and Johnston, B.H. (2007). shRNAs targeting hepatitis C: effects of sequence and structural features, and comparison with siRNA. Oligonucleotides 17, 223–236.
18. Cookeley, W.G., Piratsivitch, T., Lee, S.D., Mahachai, V., Chao, Y.C., Tannwadee, T., Chutaputti, A., Chang, W.Y., Zahn, F.E., and Puck, N. (2003). Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J. Viral Hepat. 10, 298–305.
19. Aoyub, W.S., and Keeffe, E.B. (2008). Review article: current antiviral therapy of chronic hepatitis B. Aliment. Pharmacol. Ther. 28, 167–177.
20. Feld, J.J., and Hoofnagle, J.H. (2005). Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436, 967–972.
21. Izquierdo, M. (2005). Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther. 12, 217–227.
22. Wang, B.X., Rahbar, R., and Fish, E.N. (2011). Interferon: current status and future prospects in cancer therapy. J. Interferon Cytokine Res. 31, 545–552.
23. Pepinsky, R.B., LePage, D.J., Gill, A., Chakraborty, A., Vaidyanathan, S., Green, M., Baker, D.P., Whalley, E., Hochman, P.S., and Martin, P. (2001). Improved pharmacokinetics of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. J. Pharmacol. Exp. Ther. 297, 1059–1066.
24. Lu, S., and Cullen, B.R. (2004). Adenovirus VA1 noncoding RNA can inhibit small interfering RNA and MicroRNA biogenesis. J. Virol. 78, 12868–12876.
25. Chen, D., Murphy, B., Sun, R., and Bromberg, J.S. (2003). Adaptive and innate immune responses to gene transfer vectors: role of cytokines and chemokines in vector function. Gene Ther. 10, 991–998.
26. Palmer, D.J., and Ng, P. (2005). Helper-dependent adenoviral vectors for gene therapy. Hum. Gene Ther. 16, 1–16.
27. Hosono, T., Mizuguchi, H., Katayama, K., Xu, Z.L., Sakurai, F., Ishii-Watabe, A., Kawabata, K., Yamaguchi, T., Nakagawa, S., Hayakawa, T., et al. (2006). Adenovirus vector-mediated doxycycline-inducible RNA interference. Hum. Gene Ther. 15, 813–819.
28. Machitani, M., Katayama, K., Sakurai, F., Matsui, H., Yamaguchi, T., Suzuki, T., Miyoshi, H., Kawabata, K., and Mizuguchi, H. (2011). Development of an adenovirus vector lacking the expression of virus-associated RNAs. J. Control. Release 154, 285–289.
35. Mizuguchi, H., and Kay, M.A. (1998). Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum. Gene Ther. 9, 2577–2583.
36. Mizuguchi, H., and Kay, M.A. (1999). A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum. Gene Ther. 10, 2013–2017.
37. Machitani, M., Sakurai, F., Wakabayashi, K., Tomita, K., Tachibana, M., and Mizuguchi, H. (2016). Dicer functions as an antiviral system against human adenoviruses via cleavage of adenovirus-encoded noncoding RNA. Sci. Rep. 6, 27598.
38. Machitani, M., Sakurai, F., Wakabayashi, K., Nakatani, K., Shimizu, K., Tachibana, M., and Mizuguchi, H. (2016). NF-κB promotes leaky expression of adenovirus genes in a replication-incompetent adenovirus vector. Sci. Rep. 6, 19922.
39. Kinoshita, E., Kinoshita-Kikuta, E., and Koke, T. (2009). Separation and detection of large phosphoproteins using Phos-tag SDS-PAGE. Nat. Protoc. 4, 1513–1521.